The Efficacy of Oral Melatonin in Preventing Postoperative Delirium for Patients Undergoing Orthopedic Surgery Under General Anesthesia

Sponsor
University of Baghdad (Other)
Overall Status
Completed
CT.gov ID
NCT05236907
Collaborator
(none)
36
2
3
4
18
4.5

Study Details

Study Description

Brief Summary

Postoperative delirium is a complication that should not be underestimated. As it elaborates many complications that could be avoided when an accurate assessment of the risk factors and interventional measures are taken appropriately when needed.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Delirium is a variation in concentration capabilities that occurs acutely in association with a disturbed level of consciousness. Delirium is more common in orthopaedic surgery patients than in general surgery patients. As delirium ratios range from 44% to 55% in hip surgery patients, otherwise only 10%-14% of general surgery patients. Several studies were carried out and found that melatonin levels correlate with the development of delirium postoperatively. This study was conducted to determine the efficacy of administering melatonin preoperatively in patients undergoing orthopedic surgery to prevent postoperative delirium.

Study Design

Study Type:
Interventional
Actual Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients were divided into three groups at random, with 12 patients in each group, using a double-blinded method.Patients were divided into three groups at random, with 12 patients in each group, using a double-blinded method.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
It has been done on all the study's contributors and workers.
Primary Purpose:
Prevention
Official Title:
The Efficacy of Oral Melatonin in Preventing Postoperative Delirium for Patients Undergoing Orthopedic Surgery Under General Anesthesia
Actual Study Start Date :
Jul 1, 2020
Actual Primary Completion Date :
Oct 30, 2020
Actual Study Completion Date :
Nov 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Control Group

Patients in this group received nothing for sedation.

Other: No intervention
No intervention was used.

Active Comparator: Midazolam group

7.5 mg of Midazolam were given orally the night before operation. Another dose 90 min. preoperatively.

Drug: Midazolam
7.5 mg of Midazolam orally.

Experimental: Melatonin group

5 mg of Melatonin were given orally the night before operation. Another dose 90 min. preoperatively

Drug: Melatonin
The patients were assessed using the Memorial Delirium Assessment Scale (MDAS) after the operation at 30, 60, and 90 min. Melatonin was shown to reduce delirium from 41.6% to 16.6% at 60 minutes, and the significant reduction was at 90 minutes (0%) when compared to both groups. Thus, melatonin was found to be successful in decreasing postoperative delirium when administered preoperatively.
Other Names:
  • Midazolam
  • Outcome Measures

    Primary Outcome Measures

    1. The efficacy of oral Melatonin in preventing Postoperative Delirium after general anesthesia [1 week]

      This interventional trial is done to determine the efficacy of preoperative melatonin administration in reducing postoperative delirium rates.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    60 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1- Patients in good general health. 2. Baseline MDAS <13. 3. No seizure disorder.

    Exclusion Criteria:
    1. Patients with a neurological disorder (e.g., dementia, stroke, epilepsy).

    2. Patients with a history of acute or chronic confusion.

    3. Patients taking centrally acting drugs (e.g., antidepressants, antiparkinsonian drugs, sedatives, monoamine oxidase inhibitors), or alcohol abusers.

    4. Patients who have medical disorders predisposing to delirium (e.g. cachexia, thyroid dysfunction, renal failure).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Al-Kadhemya Private Hospital Baghdad Iraq 10047
    2 Ghazi Al-Hariri Teaching Hospital Baghdad Iraq 10047

    Sponsors and Collaborators

    • University of Baghdad

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hashim Talib Hashim, Principal Investigator, University of Baghdad
    ClinicalTrials.gov Identifier:
    NCT05236907
    Other Study ID Numbers:
    • Melatonin123
    First Posted:
    Feb 11, 2022
    Last Update Posted:
    Feb 11, 2022
    Last Verified:
    Feb 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Hashim Talib Hashim, Principal Investigator, University of Baghdad
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 11, 2022